Trials / Unknown
UnknownNCT04175080
Clinical Significance and Diagnosis of Sarcopenia in Cardiac Patients
Clinical Significance and Diagnosis of Sarcopenia in Patients With Heart Failure With Preserved Ejection Fraction
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 190 (estimated)
- Sponsor
- Medical University of Lodz · Academic / Other
- Sex
- All
- Age
- 35 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
Obesity sarcopenia, characterized by the coexistence of excess fat and muscle mass reduction, may contribute to the pathophysiology of exercise intolerance in patients with heart failure with preserved ejection fraction (HFpEF). The project will examine the impact of selected circulating miRNAs on processes that may form the pathophysiological basis for HFpEF development and obesity sarcopenia in correlation with biochemical markers, echocardiographic assessment and non-invasive assessment of hemodynamic parameters. In addition, the impact of LDL and HDL on these diseases will be assessed. Determinations of selected adipokines and asymmetric dimethylarginine will also be carried out and their effects on the cardiovascular system will be assessed.
Conditions
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2019-08-31
- Completion
- 2019-11-01
- First posted
- 2019-11-22
- Last updated
- 2019-11-22
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT04175080. Inclusion in this directory is not an endorsement.